Artificial heart This technologically advanced pneumatic Phoenix-7 Total Artificial Heart was manufactured by a Taiwanese dentist Kelvin K. Cheng, a Chinese physician T. M. Kao and colleagues at the Taiwan TAH Research Center in Tainan, Republic of China (Taiwan). With this experimental artificial heart, the patient's BP was maintained at 90-100/40-55 mmHg and cardiac output at 4.2–5.8 L/min. The patient then received the world's first successful combined heart and kidney transplantation after bridging with a total artificial heart. The first AbioCor to be surgically implanted in a patient was on July 3, 2001. SynCardia is a company based in Tucson, Arizona which
Human artificial chromosome artificial chromosome vectors. The first is to create a small minichromosome by altering a natural human chromosome. This is accomplished by truncating the natural chromosome, followed by the introduction of unique genetic material via the Cre-Lox system of recombination. The second method involves the literal creation of a novel chromosome "de novo". Progress regarding "de novo" HAC formation has been limited, as many large genomic fragments will not successfully integrate into "de novo" vectors. Another factor limiting "de novo" vector formation is limited knowledge of what elements are required for construction, specifically centromeric sequences. A 2009 study has shown additional